Floatz logo

Ipilimumab

Refractory Pediatric Solid Tumor

Children's National Research Institutemonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Refractory Pediatric Solid Tumor cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Malika Kapadia
Phase 2BB
gw786034
Samsung Medical Center
Phase 2B
Ifosfamide
Samsung Medical Center
Phase 2B
Carboplatin
Samsung Medical Center
Phase 2B
Imatinib
Samsung Medical Center
Phase 2CCC

View all 14 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →